LY 223982Alternative Names: CGS 23131; SKF 107324
Latest Information Update: 29 Aug 1997
At a glance
- Originator Eli Lilly
- Class Antiasthmatics; Antipsoriatics; Benzophenones
- Mechanism of Action Leukotriene B4 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma; Psoriasis; Rheumatic disorders
Most Recent Events
- 29 Aug 1997 Discontinued-II for Psoriasis in USA (Unknown route)